| Year |
Citation |
Score |
| 2024 |
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, et al. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. Neurology. PMID 38280392 DOI: 10.1016/S1474-4422(23)00454-4 |
0.339 |
|
| 2023 |
Saft C, Burgunder JM, Dose M, Jung HH, Katzenschlager R, Priller J, Nguyen HP, Reetz K, Reilmann R, Seppi K, Landwehrmeyer GB. Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society). Neurological Research and Practice. 5: 61. PMID 37968732 DOI: 10.1186/s42466-023-00285-1 |
0.319 |
|
| 2023 |
Lunven M, Hernandez Dominguez K, Youssov K, Hamet Bagnou J, Fliss R, Vandendriessche H, Bapst B, Morgado G, Remy P, Schubert R, Reilmann R, Busse M, Craufurd D, Massart R, Rosser A, et al. A new approach to digitized cognitive monitoring: validity of the SelfCog in Huntington's disease. Brain Communications. 5: fcad043. PMID 36938527 DOI: 10.1093/braincomms/fcad043 |
0.344 |
|
| 2022 |
Hare E, Bachoud-Lévi AC, Reilmann R, Craufurd D, Busse M, Rosser A, McLauchlan D. Cognitive processes of apathy in Huntington's disease show high sensitivity to disease progression. Clinical Parkinsonism & Related Disorders. 7: 100168. PMID 36405870 DOI: 10.1016/j.prdoa.2022.100168 |
0.335 |
|
| 2020 |
Gaßner H, Jensen D, Marxreiter F, Kletsch A, Bohlen S, Schubert R, Muratori LM, Eskofier B, Klucken J, Winkler J, Reilmann R, Kohl Z. Correction to: Gait variability as digital biomarker of disease severity in Huntington's disease. Journal of Neurology. PMID 32221775 DOI: 10.1007/S00415-020-09789-1 |
0.699 |
|
| 2020 |
Gaßner H, Jensen D, Marxreiter F, Kletsch A, Bohlen S, Schubert R, Muratori LM, Eskofier B, Klucken J, Winkler J, Reilmann R, Kohl Z. Gait variability as digital biomarker of disease severity in Huntington's disease. Journal of Neurology. PMID 32048014 DOI: 10.1007/S00415-020-09725-3 |
0.743 |
|
| 2019 |
Reilmann R. Parkinsonism in Huntington's disease. International Review of Neurobiology. 149: 299-306. PMID 31779817 DOI: 10.1016/bs.irn.2019.10.006 |
0.35 |
|
| 2019 |
Schaeffer E, Streich S, Wurster I, Schubert R, Reilmann R, Wolfram S, Berg D. How to evaluate effects of occupational therapy - lessons learned from an exploratory randomized controlled trial. Parkinsonism & Related Disorders. 67: 42-47. PMID 31621606 DOI: 10.1016/J.Parkreldis.2019.09.013 |
0.314 |
|
| 2019 |
Ross CA, Reilmann R, Cardoso F, McCusker EA, Testa CM, Stout JC, Leavitt BR, Pei Z, Landwehrmeyer B, Martinez A, Levey J, Srajer T, Bang J, Tabrizi SJ. Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. Movement Disorders Clinical Practice. 6: 541-546. PMID 31538087 DOI: 10.1002/Mdc3.12808 |
0.366 |
|
| 2019 |
Medzech S, Sass C, Bohlen S, Lange HW, Koch R, Schubert R, Ringelstein EB, Reilmann R. Impaired Isometric Force Matching in Upper and Lower Limbs Revealed by Quantitative Motor Assessments in Huntington's Disease. Journal of Huntington's Disease. PMID 31450507 DOI: 10.3233/Jhd-190354 |
0.466 |
|
| 2019 |
Hohenfeld C, Dogan I, Schubert R, Didszun C, Schöls L, Synofzik M, Giordano IA, Klockgether T, Schulz JB, Reilmann R, Reetz K. Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. Cerebellum (London, England). PMID 31441004 DOI: 10.1007/S12311-019-01073-X |
0.409 |
|
| 2019 |
Langbehn DR, Stout JC, Gregory S, Mills JA, Durr A, Leavitt BR, Roos RAC, Long JD, Owen G, Johnson HJ, Borowsky B, Craufurd D, Reilmann R, Landwehrmeyer GB, Scahill RI, et al. Association of CAG Repeats With Long-term Progression in Huntington Disease. Jama Neurology. PMID 31403680 DOI: 10.1001/Jamaneurol.2019.2368 |
0.394 |
|
| 2019 |
Bachoud-Lévi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D, Squitieri F, Seppi K, Perrine C, Scherer-Gagou C, Audrey O, et al. International Guidelines for the Treatment of Huntington's Disease. Frontiers in Neurology. 10: 710. PMID 31333565 DOI: 10.3389/Fneur.2019.00710 |
0.395 |
|
| 2019 |
van der Plas E, Schubert R, Reilmann R, Nopoulos PC. A Feasibility Study of Quantitative Motor Assessments in Children Using the Q-Motor Suite. Journal of Huntington's Disease. PMID 31256146 DOI: 10.3233/Jhd-190353 |
0.388 |
|
| 2019 |
Klehmet J, Beutner S, Hoffmann S, Dornauer M, Paul F, Reilmann R, Brandt AU, Meisel A. Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. Bmc Neurology. 19: 118. PMID 31176377 DOI: 10.1186/S12883-019-1339-X |
0.447 |
|
| 2019 |
Drew CJG, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, Playle R, Griffin BA, Kelson M, Schubert R, Muratori L, Reilmann R, Rosser A, Busse M. Physical ACtivity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease. Physical Therapy. PMID 31101920 DOI: 10.1093/Ptj/Pzz075 |
0.682 |
|
| 2019 |
Matheis T, Evinger C, Schubert R, Mazzola S, Fels M, Kemper N, Reilmann R, Muratori L. Biological Motion Perception in Huntington's Disease. Journal of Huntington's Disease. PMID 31033464 DOI: 10.3233/Jhd-180337 |
0.687 |
|
| 2019 |
Espay AJ, Hausdorff JM, Sánchez-Ferro Á, Klucken J, Merola A, Bonato P, Paul SS, Horak FB, Vizcarra JA, Mestre TA, Reilmann R, Nieuwboer A, Dorsey ER, Rochester L, Bloem BR, et al. A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30901495 DOI: 10.1002/Mds.27671 |
0.317 |
|
| 2019 |
Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, et al. The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30901492 DOI: 10.1002/Mds.27673 |
0.346 |
|
| 2019 |
Quarrell OWJ, Nance MA, Nopoulos P, Reilmann R, Oosterloo M, Tabrizi SJ, Furby H, Saft C, Roos RAC, Squitieri F, Landwehrmeyer GB, Burgunder JM. Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30788860 DOI: 10.1002/Mds.27640 |
0.376 |
|
| 2019 |
Rieke L, Fels M, Schubert R, Habbel B, Matheis T, Schuldenzucker V, Kemper N, Reilmann R. Activity Behaviour of Minipigs Transgenic for the Huntington Gene. Journal of Huntington's Disease. PMID 30689591 DOI: 10.3233/Jhd-180325 |
0.381 |
|
| 2019 |
Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB, et al. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. The Lancet. Neurology. 18: 165-176. PMID 30563778 DOI: 10.1016/S1474-4422(18)30391-0 |
0.407 |
|
| 2018 |
Winder JY, Roos RAC, Burgunder JM, Marinus J, Reilmann R. Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification. Movement Disorders Clinical Practice. 5: 290-295. PMID 30363437 DOI: 10.1002/Mdc3.12618 |
0.447 |
|
| 2018 |
Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT. Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. Movement Disorders Clinical Practice. 5: 111-117. PMID 30363393 DOI: 10.1002/Mdc3.12571 |
0.422 |
|
| 2018 |
Jeppesen Kragh F, Bruun M, Budtz-Jørgensen E, Hjermind LE, Schubert R, Reilmann R, Nielsen JE, Hasselbalch SG. Quantitative Measurements of Motor Function in Alzheimer's Disease, Frontotemporal Dementia, and Dementia with Lewy Bodies: A Proof-of-Concept Study. Dementia and Geriatric Cognitive Disorders. 46: 168-179. PMID 30257254 DOI: 10.1159/000492860 |
0.373 |
|
| 2018 |
Reilmann R, Schubert R, Bohlen S, Sass C. On the rise: Quantitative measures in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 33: 1370-1371. PMID 30230629 DOI: 10.1002/Mds.27469 |
0.384 |
|
| 2018 |
Rieke L, Schubert R, Matheis T, Muratori LM, Motlik J, Schramke S, Fels M, Kemper N, Schuldenzucker V, Reilmann R. Vocalisation as a Viable Assessment for Phenotyping Minipigs Transgenic for the Huntington Gene? Journal of Huntington's Disease. 7: 269-278. PMID 30103340 DOI: 10.3233/Jhd-170284 |
0.708 |
|
| 2018 |
Reilmann R, Schuldenzucker V. Minipigs as a Large-Brained Animal Model for Huntington's Disease: From Behavior and Imaging to Gene Therapy. Methods in Molecular Biology (Clifton, N.J.). 1780: 241-266. PMID 29856023 DOI: 10.1007/978-1-4939-7825-0_13 |
0.363 |
|
| 2018 |
Schuldenzucker V, Schubert R, Muratori LM, Freisfeld F, Rieke L, Matheis T, Schramke S, Motlik J, Kemper N, Radespiel U, Reilmann R. Behavioral Assessment of Stress Compensation in Minipigs Transgenic for the Huntington Gene Using Cortisol Levels: A Proof-of-Concept Study. Journal of Huntington's Disease. 7: 151-161. PMID 29843247 DOI: 10.3233/Jhd-180285 |
0.703 |
|
| 2018 |
Valcárcel-Ocete L, Fullaondo A, Alkorta-Aranburu G, García-Barcina M, Roos RAC, Hjermind LE, Saft C, Frontali M, Reilmann R, Rickards H, Zubiaga AM, Aguirre A. Does arterial hypertension influence the onset of Huntington's disease? Plos One. 13: e0197975. PMID 29791508 DOI: 10.1371/Journal.Pone.0197975 |
0.434 |
|
| 2018 |
Kieburtz K, Reilmann R, Olanow CW. Huntington's disease: Current and future therapeutic prospects. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29737569 DOI: 10.1002/Mds.27363 |
0.384 |
|
| 2018 |
Beckmann H, Bohlen S, Saft C, Hoffmann R, Gerss J, Muratori L, Ringelstein EB, Landwehrmeyer GB, Reilmann R. Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study. Gait & Posture. 62: 451-457. PMID 29660633 DOI: 10.1016/J.Gaitpost.2018.03.039 |
0.744 |
|
| 2018 |
Minkova L, Gregory S, Scahill RI, Abdulkadir A, Kaller CP, Peter J, Long JD, Stout JC, Reilmann R, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S. Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. Neuroimage. Clinical. 17: 312-324. PMID 29527479 DOI: 10.1016/J.Nicl.2017.10.023 |
0.436 |
|
| 2018 |
Rieke L, Schubert R, Matheis T, Muratori L, Freisfeld F, Motlik J, Fels M, Kemper N, Schuldenzucker V, Reilmann R. B11 Vocalisation as a viable assessment for minipigs transgenic for the huntington gene Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.63 |
0.725 |
|
| 2018 |
Bohlen S, Paty I, Volteau M, Meyer I, Rein W, Kosinski C, Reilmann R. J07 What can we learn from a phase ii study with BN82451B in hd beyond safety and tolerability – clinical versus objective motor measures Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.267 |
0.412 |
|
| 2018 |
Delnomdedieu M, Tan Y, Ogden A, Berger Z, Reilmann R. J06 A randomized, double-blind, placebo-controlled phase ii efficacy and safety study of the PDE10A inhibitor PF-02545920 in huntington disease (amaryllis) Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.266 |
0.384 |
|
| 2018 |
Reilmann R, Gordon MF, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Rynkowski G, Volkinshtein R, Savola J. J05 Legato-hd study: a phase 2 study assessing the efficacy and safety of laquinimod as a treatment for huntington disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.265 |
0.367 |
|
| 2018 |
Massart R, Ferreira J, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, Michele GD, Rae D, Squitieri F, Seppi K, Burgunder J, Bachoud-Lévi A. H01 Upcoming international guidelines in huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.182 |
0.376 |
|
| 2018 |
Jensen D, Gassner H, Spital L, Raulet P, Kletsch A, Bohlen S, Schubert R, Muratori LM, Eskofier B, Klucken J, Winkler J, Reilmann R, Kohl Z. F65 Mobile sensor-based gait analysis provides objective motor assessments in huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.166 |
0.737 |
|
| 2018 |
Schubert R, Rosser A, Bachoud-Lévi A, Craufurd D, Reilmann R. F63 Preliminary results from Q-MOTOR/Q-COG analyses in the repair-hd study Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.164 |
0.419 |
|
| 2018 |
McMillan I, McLauchlan D, Busse M, Bachoud-Lévi A, Reilmann R, Rosser A, Craufurd D. F57 Psychiatric symptoms in huntington’s disease: correlations between interview and self-report measures in the capit-hd2 beta-testing study Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.158 |
0.386 |
|
| 2018 |
McMillan I, McLauchlan D, Busse M, Bachoud-Lévi A, Reilmann R, Rosser A, Craufurd D. F56 Psychiatric symptoms in huntington’s disease: relationship to disease stage in the CAPIT-HD2 beta-testing study Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.157 |
0.453 |
|
| 2018 |
Massart R, Busse M, Craufurd D, Reilmann R, Rosser A, Bachoud-Lévi A. F55 Repair-hd project – WP5: preparation for clinical intervention Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.156 |
0.4 |
|
| 2018 |
Massart R, Lunven M, Hamet J, Gabadinho A, Reilmann R, Busse M, Craufurd D, Rosser A, Audureau E, Bachoud-Lévi A. F30 Ecog: digitalised assessment of cognitive decline in huntington’s disease (HD) Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.134 |
0.345 |
|
| 2018 |
Lange H, Bohlen S, Reilmann R. F06 When and how does manifest hd begin? a comparison of age at onset of motor and non-motor symptoms Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.112 |
0.359 |
|
| 2017 |
Schuldenzucker V, Schubert R, Muratori LM, Freisfeld F, Rieke L, Matheis T, Schramke S, Motlik J, Kemper N, Radespiel U, Reilmann R. Behavioral testing of minipigs transgenic for the Huntington gene-A three-year observational study. Plos One. 12: e0185970. PMID 29016656 DOI: 10.1371/Journal.Pone.0185970 |
0.706 |
|
| 2017 |
Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ. Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. Jama Neurology. PMID 28975278 DOI: 10.1001/Jamaneurol.2017.2107 |
0.411 |
|
| 2017 |
Reilmann R, Schubert R. Motor outcome measures in Huntington disease clinical trials. Handbook of Clinical Neurology. 144: 209-225. PMID 28947119 DOI: 10.1016/B978-0-12-801893-4.00018-3 |
0.449 |
|
| 2017 |
Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C. Design optimization for clinical trials in early-stage manifest Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28906031 DOI: 10.1002/Mds.27122 |
0.375 |
|
| 2017 |
Kragh FJ, Hasselbalch SG, Nielsen JE, Bruun M, Reilmann R, Schubert R. [P4–142]: QUANTITATIVE MEASUREMENTS OF MOTOR FUNCTION IN ALZHEIMER's DISEASE, FRONTOTEMPORAL DEMENTIA, AND LEWY BODY DEMENTIA: A PROOF‐OF‐CONCEPT STUDY Alzheimers & Dementia. 13: 1311. DOI: 10.1016/J.Jalz.2017.06.2008 |
0.379 |
|
| 2016 |
Reilmann R. Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease. Jama Neurology. PMID 27749952 DOI: 10.1001/Jamaneurol.2016.3916 |
0.383 |
|
| 2016 |
Orth M, Gregory S, Scahill RI, Mayer IS, Minkova L, Klöppel S, Seunarine KK, Boyd L, Borowsky B, Reilmann R, Bernhard Landwehrmeyer G, Leavitt BR, Roos RA, Durr A, Rees G, et al. Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease. Human Brain Mapping. PMID 27477323 DOI: 10.1002/Hbm.23332 |
0.426 |
|
| 2016 |
Jacobs M, Hart EP, van Zwet EW, Bentivoglio AR, Burgunder JM, Craufurd D, Reilmann R, Saft C, Roos RA. Progression of motor subtypes in Huntington's disease: a 6-year follow-up study. Journal of Neurology. 263: 2080-5. PMID 27435968 DOI: 10.1007/S00415-016-8233-X |
0.443 |
|
| 2016 |
Quinn L, Hamana K, Kelson M, Dawes H, Collett J, Townson J, Roos R, van der Plas AA, Reilmann R, Frich JC, Rickards H, Rosser A, Busse M. A randomized, controlled trial of a multi-modal exercise intervention in Huntington's disease. Parkinsonism & Related Disorders. PMID 27423921 DOI: 10.1016/J.Parkreldis.2016.06.023 |
0.332 |
|
| 2016 |
Andrzejewski KL, Dowling AV, Stamler D, Felong TJ, Harris DA, Wong C, Cai H, Reilmann R, Little MA, Gwin JT, Biglan KM, Dorsey ER. Wearable Sensors in Huntington Disease: A Pilot Study. Journal of Huntington's Disease. PMID 27341134 DOI: 10.3233/Jhd-160197 |
0.478 |
|
| 2016 |
Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, et al. Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27125836 DOI: 10.1002/Mds.26642 |
0.38 |
|
| 2016 |
Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ. Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. Plos Currents. 8. PMID 26819833 DOI: 10.1371/Currents.Hd.8060298Fac1801B01Ccea6Acc00F97Cb |
0.363 |
|
| 2016 |
Schuldenzucker V, Schubert R, Freisfeld F, Rieke L, Matheis T, Motlik J, Schramke S, Reilmann R. C14 A stress level test as part of an assessment battery for phenotyping minipigs transgenic for huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.94 |
0.336 |
|
| 2016 |
Rieke L, Schramke S, Matheis T, Schubert R, Freisfeld F, Motlik J, Schuldenzucker V, Reilmann R. C12 A new setup of the discrimination test as part of an assessment battery for phenotyping minipigs transgenic for huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.92 |
0.335 |
|
| 2016 |
Schuldenzucker V, Schubert R, Freisfeld F, Rieke L, Matheis T, Motlik J, Schramke S, Reilmann R. C10 Behavioural phenotyping of minipigs transgenic for the huntington gene Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.90 |
0.364 |
|
| 2016 |
Bohlen S, Mühlbäck A, Marquard R, Saß C, Reetz K, Schiefer J, Saft C, Kohl Z, Bonelli R, Münchau A, Klebe S, Weindl A, Storch A, Löhle M, Klopstock T, ... ... Reilmann R, et al. M4 Safety and tolerability of BN82451B in huntington’s disease Journal of Neurology, Neurosurgery & Psychiatry. 87: A102.2-A103. DOI: 10.1136/Jnnp-2016-314597.289 |
0.341 |
|
| 2016 |
Papoutsi M, Weiskopf N, Langbehn D, Reilmann R, Rees G, Tabrizi SJ. A17 HD brain-train: neuroplasticity as a target to improve function in huntington’s disease Journal of Neurology, Neurosurgery & Psychiatry. 87: A5.3-A5. DOI: 10.1136/Jnnp-2016-314597.17 |
0.31 |
|
| 2016 |
Muratori LM, Evinger L, Reilmann R. F3 Biological motion perception in huntington’s disease Journal of Neurology, Neurosurgery & Psychiatry. 87: A49.2-A49. DOI: 10.1136/Jnnp-2016-314597.138 |
0.692 |
|
| 2016 |
Schubert R, Weber N, Reilmann R. F1 Q-COG – a cognitive assessment battery for huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.136 |
0.421 |
|
| 2016 |
Jacobs M, Hart EP, Zwet EWv, Bentivoglio AR, Burgunder J, Craufurd D, Reilmann R, Saft C, Roos RA. E2 Progression of motor subtypes in huntington’s disease: a six-year follow-up study Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.128 |
0.405 |
|
| 2016 |
Ross CA, Reilmann R. E1 Diagnostic criteria for huntington’s disease based on natural history Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.127 |
0.471 |
|
| 2016 |
Gregory S, Klöppel S, Scheller E, Minkova L, Razi A, Durr A, Roos RA, Leavitt BR, Papoutsi M, Landwehrmeyer GB, Reilmann R, Borowsky B, Johnson H, Mills JA, Owen G, et al. D22 Compensation in preclinical huntington’s disease: evidence from the track-on HD study Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.121 |
0.375 |
|
| 2015 |
Hoffmann S, Siedler J, Brandt AU, Piper SK, Kohler S, Sass C, Paul F, Reilmann R, Meisel A. Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. Bmc Neurology. 15: 265. PMID 26701600 DOI: 10.1186/S12883-015-0517-8 |
0.435 |
|
| 2015 |
Schramke S, Schuldenzucker V, Schubert R, Frank F, Wirsig M, Ott S, Motlik J, Fels M, Kemper N, Hölzner E, Reilmann R. Behavioral phenotyping of minipigs transgenic for the Huntington gene. Journal of Neuroscience Methods. PMID 26688470 DOI: 10.1016/J.Jneumeth.2015.11.013 |
0.391 |
|
| 2015 |
Schubert R, Frank F, Nagelmann N, Liebsch L, Schuldenzucker V, Schramke S, Wirsig M, Johnson H, Kim EY, Ott S, Hölzner E, Demokritov SO, Motlik J, Faber C, Reilmann R. Neuroimaging of a minipig model of Huntington's disease: Feasibility of volumetric, diffusion-weighted and spectroscopic assessments. Journal of Neuroscience Methods. PMID 26658298 DOI: 10.1016/J.Jneumeth.2015.11.017 |
0.392 |
|
| 2015 |
Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, Roos RA, Leavitt BR, Papoutsi M, Landwehrmeyer GB, Reilmann R, Borowsky B, Johnson H, Mills JA, Owen G, et al. Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. Ebiomedicine. 2: 1420-9. PMID 26629536 DOI: 10.1016/J.Ebiom.2015.08.002 |
0.411 |
|
| 2015 |
Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, Reilmann R, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI. The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia. PMID 26519555 DOI: 10.1016/J.Neuropsychologia.2015.10.033 |
0.361 |
|
| 2015 |
Holtbernd F, Deppe M, Bachmann R, Mohammadi S, Ringelstein EB, Reilmann R. Deficits in tongue motor control are linked to microstructural brain damage in multiple sclerosis: a pilot study. Bmc Neurology. 15: 190. PMID 26450403 DOI: 10.1186/S12883-015-0451-9 |
0.403 |
|
| 2015 |
Reilmann R, Lippross V, Hölzner E, Gigengack F, Bohlen S, Kugel H, Deppe M, Osada N, Lücke M, Riess O, Nguyen HP, Von Hörsten S, Schäfers K, Schäfers M, Jacobs AH, et al. FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study. Journal of Huntington's Disease. 4: 37-47. PMID 26333256 DOI: 10.3233/Jhd-130084 |
0.313 |
|
| 2015 |
Maetzler W, Ellerbrock M, Heger T, Sass C, Berg D, Reilmann R. Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. Plos One. 10: e0123914. PMID 25902182 DOI: 10.1371/Journal.Pone.0123914 |
0.369 |
|
| 2015 |
Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Dar Santos R, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, Reilmann R, Johnson HJ, Hayden MR, Tabrizi SJ, et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 393-401. PMID 25690257 DOI: 10.1002/Mds.26118 |
0.412 |
|
| 2015 |
Reilmann R, Rouzade-Dominguez ML, Saft C, Süssmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 427-31. PMID 25689146 DOI: 10.1002/Mds.26174 |
0.366 |
|
| 2014 |
Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1419-28. PMID 25216371 DOI: 10.1002/Mds.26021 |
0.39 |
|
| 2014 |
Reilmann R, Leavitt BR, Ross CA. Huntington's disease: a field on the move. Introduction. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1333-4. PMID 25164859 DOI: 10.1002/Mds.26017 |
0.344 |
|
| 2014 |
Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1335-41. PMID 25164527 DOI: 10.1002/Mds.26011 |
0.479 |
|
| 2014 |
Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews. Neurology. 10: 204-16. PMID 24614516 DOI: 10.1038/Nrneurol.2014.24 |
0.322 |
|
| 2014 |
Reilmann R, Rouzade-Dominguez M, Saft C, Sussmuth S, Priller J, Rosser A, Rickards H, Schols L, Pezous N, Gasparini F, Landwehrmeyer G, Johns D, Gomez-Mancilla B. N03 Efficacy, Safety, And Tolerability Of Afq056 For The Treatment Of Chorea In Patients With Huntington's Disease Journal of Neurology, Neurosurgery & Psychiatry. 85: A102-A104. DOI: 10.1136/Jnnp-2014-309032.295 |
0.302 |
|
| 2013 |
Reilmann R. The pridopidine paradox in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1321-4. PMID 23847099 DOI: 10.1002/Mds.25559 |
0.394 |
|
| 2013 |
Reilmann R. Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1030-3. PMID 23674480 DOI: 10.1002/Mds.25500 |
0.371 |
|
| 2013 |
Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet. Neurology. 12: 637-49. PMID 23664844 DOI: 10.1016/S1474-4422(13)70088-7 |
0.328 |
|
| 2013 |
Hart EP, Marinus J, Burgunder JM, Bentivoglio AR, Craufurd D, Reilmann R, Saft C, Roos RA. Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1142-5. PMID 23495076 DOI: 10.1002/Mds.25422 |
0.419 |
|
| 2013 |
van den Bogaard SJ, Dumas EM, Hart EP, Milles J, Reilmann R, Stout JC, Craufurd D, Gibbard CR, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA. Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up. Ajnr. American Journal of Neuroradiology. 34: 317-22. PMID 22918430 DOI: 10.3174/Ajnr.A3303 |
0.41 |
|
| 2013 |
Reilmann R, Holtbernd F, Bachmann R, Mohammadi S, Ringelstein EB, Deppe M. Grasping multiple sclerosis: do quantitative motor assessments provide a link between structure and function? Journal of Neurology. 260: 407-14. PMID 22872165 DOI: 10.1007/S00415-012-6639-7 |
0.365 |
|
| 2013 |
Bohlen S, Ekwall C, Hellström K, Vesterlin H, Björnefur M, Wiklund L, Reilmann R. Physical therapy in Huntington's disease--toward objective assessments? European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 20: 389-93. PMID 22672573 DOI: 10.1111/J.1468-1331.2012.03760.X |
0.456 |
|
| 2013 |
Delmaire C, Dumas EM, Sharman MA, van den Bogaard SJ, Valabregue R, Jauffret C, Justo D, Reilmann R, Stout JC, Craufurd D, Tabrizi SJ, Roos RA, Durr A, Lehéricy S. The structural correlates of functional deficits in early huntington's disease. Human Brain Mapping. 34: 2141-53. PMID 22438242 DOI: 10.1002/Hbm.22055 |
0.344 |
|
| 2013 |
Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, Langbehn DR, Jones R, Leavitt BR, Roos RA, Durr A, Johnson H, Lehéricy S, Craufurd D, Kennard C, ... ... Reilmann R, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Human Brain Mapping. 34: 519-29. PMID 22102212 DOI: 10.1002/Hbm.21449 |
0.331 |
|
| 2013 |
Weber N, Koch R, Reilmann R. P75Measuring cognitive decline in Huntington's Disease: A longitudinal analysis of the Unified Huntington's Disease Rating Scale (UHDRS) cognitive battery Basal Ganglia. 3: 68. DOI: 10.1016/J.Baga.2013.01.076 |
0.348 |
|
| 2013 |
Reilmann R, Bohlen S, Saß C, Bechtel N, Jauffret C, Sturrock A, Coleman A, Read J, Say M, t’Hart E, van den Bogaard S, Archarya T, Scahill R, Johnson H, Borowsky B, et al. Q-motor – Quantitative motor assessments: Potential novel endpoints for clinical trials in pre-manifest and symptomatic Huntington's disease – 36 months longitudinal results from the multicenter TRACK-HD study Basal Ganglia. 3: 67-68. DOI: 10.1016/J.Baga.2013.01.074 |
0.348 |
|
| 2013 |
Bohlen S, Weber N, Reilmann R. Huntington's disease – Is fatigue the underlying factor of pathologic glossomotography? Basal Ganglia. 3: 67. DOI: 10.1016/J.Baga.2013.01.073 |
0.353 |
|
| 2012 |
Reilmann R. An important step towards translation of stem cell therapies in clinical applications for neurodegenerative diseases and beyond? Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1355-6. PMID 23166927 DOI: 10.1002/Mds.25141 |
0.307 |
|
| 2012 |
Reilmann R. Does chromatin modulation provide the first wet biomarker for Huntington's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 27: 473. PMID 22590715 DOI: 10.1002/Mds.24914 |
0.351 |
|
| 2012 |
Reilmann R, Rumpf S, Beckmann H, Koch R, Ringelstein EB, Lange HW. Huntington's disease: objective assessment of posture--a link between motor and functional deficits. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 555-9. PMID 22241673 DOI: 10.1002/Mds.24908 |
0.493 |
|
| 2012 |
van den Bogaard SJ, Dumas EM, Milles J, Reilmann R, Stout JC, Craufurd D, van Buchem MA, van der Grond J, Roos RA. Magnetization transfer imaging in premanifest and manifest Huntington disease. Ajnr. American Journal of Neuroradiology. 33: 884-9. PMID 22241387 DOI: 10.3174/Ajnr.A2868 |
0.377 |
|
| 2012 |
Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet. Neurology. 11: 42-53. PMID 22137354 DOI: 10.1016/S1474-4422(11)70263-0 |
0.334 |
|
| 2012 |
Bohn E, Bohlen S, Sass C, Bechtel N, Adamou E, Reilmann R, Paul F, Pfueller C. Quantitative Motor Assessment (Q-Motor) in Multiple Sclerosis Patients and Healthy Controls (P01.150) Neurology. 78: P01.150-P01.150. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.150 |
0.367 |
|
| 2012 |
Reilmann R. Huntington's disease: Towards disease modification - gaps and bridges, facts and opinions Basal Ganglia. 2: 241-248. DOI: 10.1016/J.Baga.2012.09.004 |
0.463 |
|
| 2011 |
de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 10: 1049-57. PMID 22071279 DOI: 10.1016/S1474-4422(11)70233-2 |
0.432 |
|
| 2011 |
Vaccarino AL, Sills T, Anderson KE, Biglan K, Borowsky B, Giuliano J, Guttman M, Ho AK, Kennard C, Kupchak P, Landwehrmeyer GB, Michell A, Paulsen JS, Reilmann R, van Kammen DP, et al. Assessment of motor symptoms and functional impact in prodromal and early huntington disease. Plos Currents. 2: RRN1244. PMID 21804956 DOI: 10.1371/Currents.Rrn1244 |
0.41 |
|
| 2011 |
Kandasamy M, Reilmann R, Winkler J, Bogdahn U, Aigner L. Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease. Neurology Research International. 2011: 124256. PMID 21766020 DOI: 10.1155/2011/124256 |
0.32 |
|
| 2011 |
Sitek EJ, Sołtan W, Wieczorek D, Schinwelski M, Robowski P, Reilmann R, Guzińska K, Harciarek M, Krysa W, Sławek J. Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. Journal of the International Neuropsychological Society : Jins. 17: 788-95. PMID 21729402 DOI: 10.1017/S1355617711000725 |
0.429 |
|
| 2011 |
Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2267-73. PMID 21661053 DOI: 10.1002/Mds.23816 |
0.504 |
|
| 2011 |
Reilmann R. Progression of premanifest and early Huntington's disease detectable after 1 year—does TRACK-HD open the door to disease-modifying trials in HD and beyond? Movement Disorders : Official Journal of the Movement Disorder Society. 26: 605. PMID 21648124 DOI: 10.1002/Mds.23710 |
0.425 |
|
| 2011 |
López-Sendón JL, Royuela A, Trigo P, Orth M, Lange H, Reilmann R, Keylock J, Rickards H, Piacentini S, Squitieri F, Landwehrmeyer B, Witjes-Ane MN, Jurgens CK, Roos RA, Abraira V, et al. What is the impact of education on Huntington's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1489-95. PMID 21432905 DOI: 10.1002/Mds.23385 |
0.387 |
|
| 2011 |
Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet. Neurology. 10: 31-42. PMID 21130037 DOI: 10.1016/S1474-4422(10)70276-3 |
0.477 |
|
| 2011 |
Beckmann H, Rumpf S, Bechtel N, Lange H, Saft C, Hoffmann R, Kraus P, Barth K, Trautmann S, Landwehrmeyer B, Reilmann R. Gait and posture in pre-manifest and symptomatic huntington's disease Klinische Neurophysiologie. 42. DOI: 10.1055/s-0031-1272717 |
0.318 |
|
| 2011 |
Rumpf S, Bohlen S, Bechtel N, Koch R, Lange H, Reilmann R. Postural assessement in dynamic posturography - a useful motor phenotype measure for presymptomatic and manifest Huntington disease? Klinische Neurophysiologie. 42. DOI: 10.1055/s-0031-1272714 |
0.324 |
|
| 2011 |
Horst S, Bohlen S, Lange H, Reilmann R. Impaired isometric force coordination in Huntington's disease Klinische Neurophysiologie. 42. DOI: 10.1016/J.Baga.2013.01.072 |
0.411 |
|
| 2011 |
Reilmann R. Progression of premanifest and early Huntington's disease detectable after 1 year-Does TRACK-HD open the door to disease-modifying trials in HD and beyond? Movement Disorders. 26: 605. DOI: 10.1002/mds.23710 |
0.313 |
|
| 2010 |
Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, ... ... Reilmann R, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 75: 2150-60. PMID 21068430 DOI: 10.1212/Wnl.0B013E3182020123 |
0.506 |
|
| 2010 |
Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 75: 1702-10. PMID 21060093 DOI: 10.1212/Wnl.0B013E3181Fc27E4 |
0.441 |
|
| 2010 |
Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP, Ringelstein EB, Lange HW. Grasping premanifest Huntington's disease - shaping new endpoints for new trials. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2858-62. PMID 20818671 DOI: 10.1002/Mds.23300 |
0.476 |
|
| 2010 |
Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, Auer DP, Ringelstein EB, Lange HW. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2195-202. PMID 20645403 DOI: 10.1002/Mds.23243 |
0.502 |
|
| 2010 |
Rumpf S, Bohlen S, Bechtel N, Koch R, Lange H, Reilmann R. F16 Postural assessment in dynamic posturography—a useful motor phenotype measure for presymptomatic and manifest Huntington's disease? Journal of Neurology, Neurosurgery & Psychiatry. 81: A27.3-A28. DOI: 10.1136/jnnp.2010.222620.16 |
0.301 |
|
| 2010 |
Rumpf S, Bohlen S, Bechtel N, Koch R, Lange H, Reilmann R. F15 Balance control in Huntington's disease: is the berg balance scale a useful test for clinical and quantitative motor assessment? Journal of Neurology, Neurosurgery & Psychiatry. 81: A27.2-A27. DOI: 10.1136/jnnp.2010.222620.15 |
0.319 |
|
| 2010 |
Sitek EJ, Sołtan W, Wieczorek D, Schinwelski M, Robowski P, Reilmann R, Krysa W, Sławek J. F11 Self-awareness of involuntary movements and daily living disability in huntington's disease in comparison to Parkinson's disease and cervical dystonia Journal of Neurology, Neurosurgery & Psychiatry. 81: A26.1-A26. DOI: 10.1136/Jnnp.2010.222620.11 |
0.378 |
|
| 2009 |
Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. The Lancet. Neurology. 8: 791-801. PMID 19646924 DOI: 10.1016/S1474-4422(09)70170-X |
0.477 |
|
| 2009 |
Rumpf S, Bohlen S, Ekwall C, Lange H, Reilmann R. Motor exam in Huntington's disease: is one leg stand a useful test for clinical and quantitative motor assessment? Aktuelle Neurologie. 36. DOI: 10.1055/s-0029-1238523 |
0.332 |
|
| 2009 |
Beckmann H, Rumpf S, Bechtel N, Lange H, Saft C, Hoffmann R, Kraus P, Barth K, Trautmann S, Landwehrmeyer B, Reilmann R. Objective motor phenotype assessment of gait and posture in pre-manifest and symptomatic Huntington's disease Aktuelle Neurologie. 36. DOI: 10.1055/s-0029-1238522 |
0.391 |
|
| 2009 |
Say M, Bechtel N, Sturrock A, van den Bogaard S, Jauffret C, Bohlen S, Langbehn D, Mills J, Archarya T, Johnson H, Borowsky B, Durr A, Leavitt B, Roos R, Tabrizi S, ... ... Reilmann R, et al. Quantitative motor phenotype assessment in pre-manifest and symptomatic Huntington's disease: tongue force analysis differentiates between disease stages and provides high phenotype correlation. Cross sectional results from the TRACK-HD Study Aktuelle Neurologie. 36. DOI: 10.1055/S-0029-1238518 |
0.342 |
|
| 2009 |
Bechtel N, Jauffret C, Say M, Sturrock A, van den Bogaard S, Mills J, Archarya T, Langbehn D, Johnson H, Borowsky B, Durr A, Leavitt B, Roos R, Stout J, Tabrizi S, ... ... Reilmann R, et al. Finger tapping as an objective motor phenotype marker in pre-manifest and symptomatic Huntington's disease – cross-sectional results from the TRACK-HD Study Aktuelle Neurologie. 36. DOI: 10.1055/S-0029-1238474 |
0.307 |
|
| 2008 |
Rumpf S, Beckmann H, Bohlen S, Bechtel N, Kraus P, Lange H, Reilmann R. Impairments of postural control in patient's with Huntington's disease while sitting – a new motor phenotype biomarker? Aktuelle Neurologie. 35. DOI: 10.1055/s-0028-1086866 |
0.331 |
|
| 2005 |
Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassouridis A, Bender J, Weindl A, Dose M, Gasser T, Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington's disease. Journal of Neurology. 252: 36-41. PMID 15672208 DOI: 10.1007/S00415-005-0595-4 |
0.369 |
|
| 2005 |
Kirsten F, Bohlen S, Sommer J, Merl T, Saemann P, Klopstock T, Bender A, Dose M, Weindl A, Auer D, Ringelstein E, Reilmann R. Altered isometric force control during object release in patients with Huntington's Disease Aktuelle Neurologie. 32. DOI: 10.1055/S-2005-919363 |
0.389 |
|
| 2005 |
Reilmann R. Motor deficits as biomarkers in Huntington's disease: Perspectives for neuroacanthocytosis syndromes Neuroacanthocytosis Syndromes. 233-242. DOI: 10.1007/1-4020-2898-9_26 |
0.302 |
|
| 2003 |
Muratori LM, Reilmann R, Gordon AM. Coordination of fingertip forces during precision grasping in multiple system atrophy. Neuropsychologia. 41: 1498-508. PMID 12849768 DOI: 10.1016/S0028-3932(03)00092-7 |
0.73 |
|
| 2003 |
Salimi I, Frazier W, Reilmann R, Gordon AM. Selective use of visual information signaling objects' center of mass for anticipatory control of manipulative fingertip forces. Experimental Brain Research. 150: 9-18. PMID 12698211 DOI: 10.1007/S00221-003-1394-8 |
0.733 |
|
| 2003 |
Flöel A, Reilmann R, Frese A, Lüdemann P. Anticonvulsants for Creutzfeldt-Jakob disease? Lancet. 361: 224. PMID 12547547 DOI: 10.1016/S0140-6736(03)12273-8 |
0.379 |
|
| 2001 |
Reilmann R, Gordon AM, Henningsen H. Initiation and development of fingertip forces during whole-hand grasping. Experimental Brain Research. 140: 443-52. PMID 11685397 DOI: 10.1007/S002210100838 |
0.497 |
|
| 2001 |
Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology. 57: 920-4. PMID 11552034 DOI: 10.1212/Wnl.57.5.920 |
0.616 |
|
| 2001 |
Quinn L, Reilmann R, Marder K, Gordon AM. Altered movement trajectories and force control during object transport in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 469-80. PMID 11391741 DOI: 10.1002/Mds.1108 |
0.56 |
|
| 2000 |
Gordon AM, Quinn L, Reilmann R, Marder K. Coordination of prehensile forces during precision grip in Huntington's disease. Experimental Neurology. 163: 136-48. PMID 10785452 DOI: 10.1006/Exnr.2000.7348 |
0.596 |
|
| 1999 |
Gordon AM, Reilmann R. Getting a grasp on research: does treatment taint testing of parkinsonian patients? Brain : a Journal of Neurology. 122: 1597-8. PMID 10430842 DOI: 10.1093/Brain/122.8.1597 |
0.535 |
|
| 1995 |
Reilmann R, Rolf LH, Lange HW. Decreased plasma alanine and isoleucine in Huntington's disease. Acta Neurologica Scandinavica. 91: 222-4. PMID 7793240 DOI: 10.1111/J.1600-0404.1995.Tb00438.X |
0.306 |
|
| Show low-probability matches. |